| scholarly article | Q13442814 |
| P50 | author | Carl H. June | Q19277113 |
| Marco Ruella | Q56947896 | ||
| Simon F Lacey | Q56978267 | ||
| Bruce L. Levine | Q85544154 | ||
| Tyler J Reich | Q88924956 | ||
| Terry J Fry | Q89329430 | ||
| Stephan A Grupp | Q104495066 | ||
| P2093 | author name string | Frederic D Bushman | |
| Jun Xu | |||
| John Scholler | |||
| Hans Bitter | |||
| Michael Klichinsky | |||
| Olga Shestova | |||
| David M Barrett | |||
| Farzana Nazimuddin | |||
| J Joseph Melenhorst | |||
| Shannon L Maude | |||
| Regina M Young | |||
| Irina Kulikovskaya | |||
| Joseph A Fraietta | |||
| Prachi R Patel | |||
| David E Ambrose | |||
| Elena J Orlando | |||
| Vijay G Bhoj | |||
| Christopher L Nobles | |||
| Saar I Gill | |||
| P2860 | cites work | Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. | Q51361321 |
| NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia | Q83016881 | ||
| Chimeric Antigen Receptor Therapy | Q89419402 | ||
| Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily | Q24294399 | ||
| Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor | Q24321564 | ||
| dbSNP: the NCBI database of genetic variation | Q24608672 | ||
| T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Q24632975 | ||
| Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 | ||
| Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials | Q27312288 | ||
| The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data | Q27860742 | ||
| Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies | Q28072131 | ||
| A framework for variation discovery and genotyping using next-generation DNA sequencing data | Q29547262 | ||
| COSMIC: exploring the world's knowledge of somatic mutations in human cancer | Q29615725 | ||
| Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
| Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | Q29620130 | ||
| Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies | Q30827633 | ||
| Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. | Q31048148 | ||
| Identification and characterization of fully human anti-CD22 monoclonal antibodies | Q33523255 | ||
| CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency | Q33755327 | ||
| Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy | Q34046263 | ||
| Estimating abundances of retroviral insertion sites from DNA fragment length data. | Q34124838 | ||
| Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. | Q35483880 | ||
| INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes | Q36323403 | ||
| Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy | Q36349583 | ||
| Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia | Q36619703 | ||
| Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS. | Q38649269 | ||
| Retroviral and Transposon-Based Tet-Regulated All-In-One Vectors with Reduced Background Expression and Improved Dynamic Range | Q39658146 | ||
| The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. | Q40050634 | ||
| Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. | Q40590332 | ||
| Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 | ||
| Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients | Q45875400 | ||
| An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells | Q46485190 | ||
| CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. | Q48272279 | ||
| Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | Q49029195 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 1499-1503 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | |
| P478 | volume | 24 |
| Q64053615 | 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies |
| Q100750316 | Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy |
| Q92337111 | Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia |
| Q93039755 | Advances and Challenges of CAR T Cells in Clinical Trials |
| Q61811550 | Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs? |
| Q104610983 | Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses |
| Q57471771 | CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells |
| Q58115653 | CAR antigens beyond recognition |
| Q58561244 | CAR antigens beyond recognition |
| Q75720015 | CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity |
| Q64108518 | CAR-Based Approaches to Cutaneous T-Cell Lymphoma |
| Q60913837 | Cellular Immunotherapy of Canine Cancer |
| Q64246103 | Chimeric Antigen Receptor T-Cells: The Future is Now |
| Q64062556 | Chimeric Antigen Receptors for T-Cell Malignancies |
| Q94526312 | Chimeric antigen receptor T cell therapy comes to clinical practice |
| Q59126606 | Chimeric antigen receptors: unleashing a new age of anti-cancer therapy |
| Q101139022 | Clinical CAR-T cell and Oncolytic Virotherapy for Cancer Treatment |
| Q101139018 | Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies |
| Q92615635 | Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics |
| Q90334543 | Emerging Cellular Therapies for Cancer |
| Q97531713 | Engineered off-the-shelf therapeutic T cells resist host immune rejection |
| Q60924201 | Engineering and Design of Chimeric Antigen Receptors |
| Q92059900 | Engineering strategies to overcome the current roadblocks in CAR T cell therapy |
| Q92337122 | Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors |
| Q90862859 | Genetically engineered T cells for cancer immunotherapy |
| Q92239193 | Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation |
| Q91903894 | Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia |
| Q92648785 | IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell |
| Q91208634 | Immune-Based Therapies in Acute Leukemia |
| Q89453284 | Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction |
| Q95271845 | Lipid-Mediated Insertion of Toll-Like Receptor (TLR) Ligands for Facile Immune Cell Engineering |
| Q92355805 | Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma? |
| Q92150199 | Mechanisms of resistance to CAR T cell therapy |
| Q64102615 | Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies |
| Q94467230 | New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry |
| Q97527763 | Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by γδ T Cells in Contrast to αβ T Cells |
| Q91964127 | Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy |
| Q104795247 | Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch |
| Q64117924 | Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma |
| Q90453826 | Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor |
| Q64064162 | Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response |
| Q89966656 | T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources |
| Q92285876 | TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product |
| Q92304043 | Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions |
| Q64118716 | The Emergence of Universal Immune Receptor T Cell Therapy for Cancer |
| Q92633945 | The Future: In Vivo CAR T Cell Gene Therapy |
| Q89515386 | The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 |
| Q98164353 | The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma |
| Q92826593 | Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy |
| Q92442600 | Translating Cell and Gene Biopharmaceutical Products for Health and Market Impact. Product Scaling From Clinical to Marketplace: Lessons Learned and Future Outlook |
| Q57299372 | Tumors evading CARs-the chase is on |
| Q95643106 | Ultrasensitive and rapid quantification of rare tumorigenic stem cells in hPSC-derived cardiomyocyte populations |
| Q59326961 | Universal CARs, universal T cells, and universal CAR T cells |
| Q99237801 | Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells |
| Q92826000 | γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer |
Search more.